10-Q: Vivos Therapeutics Secures $7.5 Million Investment, Pivots to Strategic Alliances

Vivos Therapeutics, Inc. reports a $7.5 million private placement and a strategic shift towards alliances with sleep centers, alongside its Q2 2024 financial results.

Summary

• Vivos Therapeutics, Inc. has filed its 10-Q for the quarter ended June 30, 2024, detailing its financial performance and strategic developments.
• The company secured a $7.5 million private placement with V-CO Investors LLC, which included common stock, pre-funded warrants, and common stock purchase warrants.
• Vivos is shifting its marketing and distribution model to focus on strategic alliances with sleep testing and treatment centers, starting with a partnership with Rebis Health Holdings, LLC.
• The company reported a net loss of $1.93 million for the three months ended June 30, 2024, and $5.69 million for the six months ended June 30, 2024.
• Revenue increased to $4.05 million for the three months ended June 30, 2024, and $7.47 million for the six months ended June 30, 2024, driven by product sales and service revenue.
• The company's cash and cash equivalents stood at $6.9 million as of June 30, 2024, which is deemed insufficient to fund operations over the next twelve months without additional financing.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the strategic shift and new investment are positive, the ongoing losses and insufficient cash raise concerns. The sentiment is neutral to slightly negative due to the financial challenges.

Positives

• The $7.5 million private placement significantly bolsters the company's cash position.
• The strategic alliance with Rebis Health Holdings, LLC, marks a significant shift in the company's marketing and distribution model.
• Revenue increased by 19% for the three months ended June 30, 2024, compared to the same period in 2023.
• Gross profit increased to $2.7 million for the three months ended June 30, 2024, compared to $2.1 million for the same period in 2023.
• General and administrative expenses decreased by approximately $1.8 million for the three months ended June 30, 2024, compared to the same period in 2023.

Negatives

• The company reported a net loss of $1.93 million for the three months ended June 30, 2024, and $5.69 million for the six months ended June 30, 2024.
• Cash and cash equivalents of $6.9 million are not sufficient to fund operations over the next twelve months without additional financing.
• The company has incurred losses since inception, resulting in an accumulated deficit of approximately $98.7 million as of June 30, 2024.
• Net cash used in operating activities was approximately $5.6 million for the six months ended June 30, 2024.
• The company experienced a decline in product sales revenue in the first half of 2024.

Risks

• The company's cash and cash equivalents are insufficient to fund operations over the next twelve months without additional financing.
• The new strategic alliance model is unproven and may not increase revenues as anticipated.
• The company is subject to risks related to inflation, the war in Ukraine, and Middle East hostilities.
• The company may be unable to maintain compliance with Nasdaq listing requirements.
• The company relies on third-party suppliers and contract manufacturers, which could lead to supply chain issues.

Future Outlook

The company anticipates that its strategic marketing and distribution alliance will positively impact revenue growth and stockholders equity in upcoming fiscal quarters. The company is also exploring additional equity capital financing to maintain compliance with Nasdaq listing requirements.

Management Comments

• Management is reviewing all options to obtain additional financing to fund operations.
• Management expects the strategic alliance with Rebis to increase patient volume, drive top line revenue and lower customer acquisition costs and overhead.

Industry Context

The company's shift towards strategic alliances reflects a broader trend in the healthcare industry towards integrated care models. The company is also addressing the growing market for sleep apnea treatments, which is driven by increasing awareness and diagnosis rates.

Comparison to Industry Standards

• Vivos's revenue growth of 19% for the three months ended June 30, 2024, is a positive sign, but it is important to compare this to the growth rates of other medical device companies in the sleep apnea space.
• The company's net loss of $5.69 million for the six months ended June 30, 2024, is significant and needs to be compared to the profitability of its competitors, such as ResMed and Philips, which are established players in the sleep apnea market.
• The company's cash position of $6.9 million is relatively low compared to larger medical device companies, which typically have substantial cash reserves to fund operations and growth initiatives.
• The strategic alliance model is a departure from the traditional sales model of many medical device companies, and its success will depend on the company's ability to execute this new strategy effectively.
• The company's reliance on third-party manufacturers is common in the medical device industry, but it also exposes the company to supply chain risks, which need to be managed carefully.

Legal Proceedings

• The company is involved in ongoing litigation with Ortho-Tain, Inc. in two separate cases.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may be affected by the company's cost-saving measures and strategic shifts.
• Customers (dentists and patients) may benefit from the company's new strategic alliance model and expanded product offerings.
• Suppliers may be impacted by changes in the company's sourcing strategy.

Next Steps

• The company will focus on implementing its strategic alliance with Rebis Health Holdings, LLC.
• The company will explore additional equity capital financing to maintain compliance with Nasdaq listing requirements.
• The company will continue to refine its product offerings and strategies to increase revenue and achieve profitability.

Key Dates

Keywords

Vivos Therapeutics, private placement, strategic alliance, sleep apnea, oral appliances, revenue, net loss, warrants, healthcare, medical devices